Tobira Therapeutics, Inc. (TBRA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile - GlobalData Financial Mergers and Acquisitions Intelligence

Tobira Therapeutics, Inc. (TBRA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Tobira Therapeutics, Inc. (TBRA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile - GlobalData Financial Mergers and Acquisitions Intelligence
Tobira Therapeutics, Inc. (TBRA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Published Sep 23, 2016
43 pages — Published Sep 23, 2016
Price US$ 250.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Tobira Therapeutics, Inc. (Tobira) is a clinical-stage biopharmaceutical company that develops and commercializes therapies for treating liver disease, inflammation, fibrosis and HIV. The companys lead product candidate, cenicriviroc (CVC), is a proprietary immunomodulator that used for treating diseases such as HIV-1, and others. Its CVC is also Phase 3-ready in HIV-1 infection with potential as the backbone in a fixed-dose combination therapy. The company's lead product candidate cenicriviroc (CVC), is evaluated for the treatment of non-alcoholic steatohepatitis (NASH) in the CENTAUR study; a global randomized Phase 2b study of CVC vs placebo in patients with NASH and liver fibrosis.

Tobira Therapeutics, Inc. (TBRA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharmaceuticals & Healthcare eTrack deals database, and primary and secondary research.


Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.


Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deal

  
Source:
Document ID
GDPH140409D
Country
Industry
Ticker
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables31
  List of Figures41
Tobira Therapeutics, Inc., Pharmaceuticals &Healthcare, Deals By Year, 2010 to YTD 201642
Tobira Therapeutics, Inc., Pharmaceuticals &Healthcare Deals By Type, 2010 to YTD 201661
Tobira Therapeutics, Inc., Pharmaceuticals &Healthcare, Deals By Region, 2010 to YTD 201671
Tobira Therapeutics, Inc., Pharmaceuticals &Healthcare, Deals By Therapy Area, 2010 to YTD 201681
Tobira Therapeutics, Inc., Medical Devices Deals, 2010 to YTD 201691
Tobira Therapeutics, Inc., Pharmaceuticals &Healthcare, Deals Summary, 2010 to YTD 2016102
Tobira Therapeutics, Inc., Pharmaceuticals &Healthcare, Deal Details1228
  Venture Financing121
    Regado Biosciences Raises US$51 Million In Series E Financing122
    Regado Biosciences Raises US$6.8 Million In Venture Financing141
    Regado Biosciences Secures US$11.6 Million In Financing151
    Tobira Therapeutics Secures US$31 Million In Series B Round Of Financing162
    Tobira Therapeutics Secures US$4 Million In Venture Financing181
    Regado Biosciences Raises US$14.55 Million In Venture Financing191
  Merger201
    Regado Biosciences Merges with Tobira Therapeutics202
  Licensing Agreements221
    Tobira Therapeutics Enters into Licensing Agreement with Dong-A for Evogliptin222
    Dong-A Enters into Licensing Agreement with Tobira Therapeutics for Cenicriviroc241
  Equity Offering251
    Tobira Therapeutics Withdraws Registration Statement for Private Placement of Shares for up to USD40 Million251
    Tobira Therapeutics Raises USD27 Million in Private Placement of Shares262
    Tobira Therapeutics Withdraws IPO282
    Regado Biosciences Completes Public Offering Of Shares For US$60 Million302
    Regado Biosciences Completes Private Placement Of Shares For US$20 Million321
    Regado Biosciences Completes Underwriters' Exercise Of Over-Allotment Option For IPO For US$43 Million332
  Debt Offering351
    Tobira Therapeutics Raises USD13 Million in Private Placement of Notes352
  Acquisition371
    Allergan to Acquire Tobira Therapeutics in Tender Offer373
Tobira Therapeutics, Inc. - Key Competitors401
Key Employees411
Locations And Subsidiaries421
  Head Office421
Appendix431
  Methodology431
  About GlobalData431
  Contact Us431
  Disclaimer431

Table Of Contents

About the Author


Cite this Report

  
MLA:
GlobalData Financial Mergers and Acquisitions Intelligence. "Tobira Therapeutics, Inc. (TBRA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile" Sep 23, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GlobalData-Financial-Mergers-and-Acquisitions-Intelligence/Tobira-Therapeutics-Inc-TBRA-Pharmaceuticals-Healthcare-Deals-and-Alliances-Profile-2148-3097>
  
APA:
GlobalData Financial Mergers and Acquisitions Intelligence. (2016). Tobira Therapeutics, Inc. (TBRA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Sep 23, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GlobalData-Financial-Mergers-and-Acquisitions-Intelligence/Tobira-Therapeutics-Inc-TBRA-Pharmaceuticals-Healthcare-Deals-and-Alliances-Profile-2148-3097>
  
US$ 250.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research